(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying
disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to
evaluate its safety, and to evaluate its effect on development of pulmonary hypertension,
quality of life, and dyspnea (shortness of breath) symptoms in this participant population.
Participants were randomized in a 2:1 ratio to receive ambrisentan or placebo, respectively.
Participation in the study was to be up to 4 years, depending on how long it would take to
enroll participants and observe study events. After randomization, visits to the clinic took
place every 3 months, and laboratory procedures were performed every month.